Tracers / [18F]AlF-FAPI-74
[18F]AlF-FAPI-74
Also written as [18F]AlF-FAPI-74; [F-18]AlF-FAPI-74
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- PET
- Production route
- —
- Stage
- —
- Syntheses indexed
- 10
What it is
- Compound class
- NOTA-conjugated FAP-inhibitor (quinoline-based small molecule) labeled via Al18F
- Target / mechanism
- Targets fibroblast activation protein (FAP) expressed on cancer-associated fibroblasts in tumor stroma PMID 34420105
- Clinical application
- PET imaging of cancer-associated fibroblasts via FAP targeting, used for tumor staging and monitoring stromal/CAF response to therapy PMID 41798720
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| AllinOne (AiO) Trasis | vendor cassette | SPE | 50.0 ± 10.3% yes | 97.1 ± 0.2% | NOTA-FAPI-74 ABX | 41391071 2025 EJNMMI Radiopharm Chem Trasis AllInOne® platform — corresponding to a decay-corrected radiochemical yield of 50.0 ± 10.3%, calculated relative to the starting activity in the target |
| In-house / custom built | — | — | 75 ± 5% | >99% | FAPI-74 | 41798720 2026 Chem Eng J the first fully-automated, droplet-based production of [18F]AlF-labeled compounds using a compact and cost-effective platform — high radiochemical yield (RCY, 75 ± 5%) |
| CFN-MPS200 Sumitomo | vendor cassette | SPE | 37.0 ± 4.3 | ≥ 97% | FAPI-74 precursor SOFIE | 34420105 2021 EJNMMI Radiopharm Chem cassette-type multi purpose synthesizer CFN-MPS200 — radiochemical yield was 37 ± 4% (n = 10) |
| In-house / custom built | — | — | 75 ± 5% | >99% | FAPI-74 | 41798720 2026 Chem Eng J report the first fully-automated, droplet-based production of [18F]AlF-labeled compounds using a compact and cost-effective platform — obtained with high radiochemical yield (RCY, 75 ± 5%) |
| — | — | HPLC | 15% | >99% | FAPI-74 | 41761350 2026 Cancer Imaging |
| AllinOne (AiO) Trasis | vendor cassette | SPE | 50.0 ± 10.3% yes | 97.1 ± 0.2% | NOTA-FAPI-74 ABX | 41391071 2025 EJNMMI Radiopharm Chem using the Trasis AllInOne® platform — corresponding to a decay-corrected radiochemical yield of 50.0 ± 10.3%, calculated relative to the starting activity in the target. |
| — | — | — | — | — | — | 41299326 2025 BMC Cancer |
| — | — | — | 18.5 ± 2.5% | >95% | — | 34050679 2021 J Labelled Comp Radiopharm first developed on the flexible GE TRACERLab FX2N (FXN) platform — radiochemical yield (RCY) of 18.5 ± 2.5% (n = 5, relative to starting [18 F]fluoride) |
| — | — | — | 20 ± 2.5% | >95% | — | 34050679 2021 J Labelled Comp Radiopharm later translated to the cassette-based module Trasis AllInOne (AIO) — production of [18 F]FAPI-74 in an isolated RCY of 20 ± 2.5% [n = 3] |
| — | — | — | — | — | — | 42627578 2026 Ann Nucl Med |
Need this precursor?We can point you to suppliers for [18F]AlF-FAPI-74, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); receptor ligand with a saturable target -> molar activity (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]AlF-FAPI-74.
Get in touchNotes
Added from reverse module search (stage 6); 3 article(s) with F-18. Compound class inferred from precursor name (not stated outright) -- PMID 41391071: 'NOTA-FAPI-74'.